Penicillin G Procaine

Pinta, Erysipelas, Yaws + 24 more
Treatment
9 FDA approvals
10 Active Studies for Penicillin G Procaine

What is Penicillin G Procaine

Procaine benzylpenicillinThe Generic name of this drug
Treatment SummaryProcaine benzylpenicillin is an injectable combination antibiotic. It is a mix of benzylpenicillin, which is naturally occurring and effective against a wide range of organisms, and procaine, a local anesthetic to reduce the pain of injection. Procaine benzylpenicillin is administered by deep intramuscular injection and is slowly absorbed and then hydrolyzed into benzylpenicillin, allowing for a slow release of the drug into the body. This drug is used to treat many infections, especially in veterinary settings, and is the drug of first choice for many infections.
Penicillin G Procaineis the brand name
Penicillin G Procaine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Penicillin G Procaine
Procaine benzylpenicillin
1948
10

Approved as Treatment by the FDA

Procaine benzylpenicillin, otherwise known as Penicillin G Procaine, is approved by the FDA for 9 uses like presenting as being moderately severe and presenting as being moderately severe to severe .
presenting as being moderately severe
Used to treat presenting as being moderately severe in combination with Benzylpenicillin
presenting as being moderately severe to severe
Used to treat presenting as being moderately severe to severe in combination with Benzylpenicillin
Scarlet Fever
Used to treat Scarlet Fever caused by susceptible streptococci in combination with Benzylpenicillin
Erysipelas
Used to treat Erysipelas caused by susceptible streptococci in combination with Benzylpenicillin
Otitis Media
Used to treat Otitis Media caused by susceptible pneumococci in combination with Benzylpenicillin
Regional Anesthetic Nerve Block
Pneumonia
Used to treat Pneumonia caused by susceptible pneumococci in combination with Benzylpenicillin
Skin Structures and Soft Tissue Infections caused by susceptible streptococci
Used to treat Skin Structures and Soft Tissue Infections caused by susceptible streptococci in combination with Benzylpenicillin
Streptococcus
Used to treat Upper Respiratory Tract Infection caused by susceptible streptococci in combination with Benzylpenicillin

Effectiveness

How Penicillin G Procaine Affects PatientsProcaine benzylpenicillin is an antibiotic used to treat bacteria that are sensitive to penicillin. It works by preventing bacteria from making their cell walls, which makes them unstable and unable to survive. It belongs to a family of antibiotics called penicillins and beta-lactams.
How Penicillin G Procaine works in the bodyProcaine benzylpenicillin is converted to penicillin G when it reaches the injection site. Penicillin G attaches to the proteins on bacterial cell walls and stops an enzyme from cross-linking peptides to the peptidoglycan backbone. This eventually causes the bacteria to break apart and die.

When to interrupt dosage

The endorsed measurement of Penicillin G Procaine is contingent upon the recognized condition, including Necrotizing ulcerative gingivostomatitis, Yaws and Regional Anesthetic Nerve Block. The dose can be located in the table below, contingent upon the technique of delivery (e.g. Injection, suspension or Powder, for solution).
Condition
Dosage
Administration
Scarlet Fever
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Streptococcus
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Primary Syphilis
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Pneumonia
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Erysipelas
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Yaws
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Respiratory Tract Infections
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
presenting as being moderately severe to severe
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Skin Structures and Soft Tissue Infections caused by susceptible streptococci
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Scarlet Fever
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Diphtheria
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Rat-Bite Fever
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Pinta
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
prophylaxis of Anthrax
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Non-venereal endemic syphilis
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
presenting as being moderately severe
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Tertiary syphilis
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Anthrax
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Necrotizing ulcerative gingivostomatitis
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular
Regional Anesthetic Nerve Block
, 1200000.0 [iU]/mL, 600000.0 [iU]/mL, 300000.0 [iU]/mL, 300000.0 units/mL
, Powder, for solution, Intramuscular, Powder, for solution - Intramuscular, Suspension - Intramuscular, Suspension, Injection, suspension, Injection, suspension - Intramuscular, Injection, Injection - Intramuscular

Warnings

Penicillin G Procaine Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Penicillin G Procaine.
Common Penicillin G Procaine Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Procaine benzylpenicillin.
Acrivastine
Minor
Procaine benzylpenicillin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Procaine benzylpenicillin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Almasilate
Minor
Procaine benzylpenicillin may decrease the excretion rate of Almasilate which could result in a higher serum level.
Antihemophilic factor (recombinant), PEGylated
Minor
Procaine benzylpenicillin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Penicillin G Procaine Toxicity & Overdose RiskProcaine benzylpenicillin can cause pain, clotting problems, and seizures. Treatment for syphilis can lead to the Jarisch-Herxheimer reaction. Skin rashes, fever, delayed serum sickness, and anaphylactic shock can also occur. The lethal dose for mice and rats is greater than 2000 mg/kg. Overdosing can cause seizures, paralysis, and death. Vomiting and stomach pumping may help if done soon after the injection. Hemodialysis can reduce high blood levels of the drug.
image of a doctor in a lab doing drug, clinical research

Penicillin G Procaine Novel Uses: Which Conditions Have a Clinical Trial Featuring Penicillin G Procaine?

Currently, four active trials are assessing the potential of Penicillin G Procaine in managing Otitis Media caused by susceptible pneumococci, Primary and Tertiary Syphilis.
Condition
Clinical Trials
Trial Phases
Diphtheria
0 Actively Recruiting
Tertiary syphilis
0 Actively Recruiting
prophylaxis of Anthrax
0 Actively Recruiting
Erysipeloid
0 Actively Recruiting
Primary Syphilis
0 Actively Recruiting
Scarlet Fever
0 Actively Recruiting
Respiratory Tract Infections
0 Actively Recruiting
Rat-Bite Fever
0 Actively Recruiting
Scarlet Fever
0 Actively Recruiting
Erysipelas
0 Actively Recruiting
presenting as being moderately severe to severe
0 Actively Recruiting
Yaws
0 Actively Recruiting
Secondary Syphilis
0 Actively Recruiting
presenting as being moderately severe
0 Actively Recruiting
Pinta
0 Actively Recruiting
Urinary Tract Infection (UTI)
8 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Pneumonia
0 Actively Recruiting
Erysipelas
0 Actively Recruiting
Bacterial Infections
0 Actively Recruiting
Streptococcus
0 Actively Recruiting

Penicillin G Procaine Reviews: What are patients saying about Penicillin G Procaine?

1.7Patient Review
6/2/2008
Penicillin G Procaine for Syphilis

Patient Q&A Section about penicillin g procaine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why is penicillin G and procaine combined?

"The combination of lidocaine and penicillin is intended to reduce the pain and discomfort associated with a large intramuscular injection of penicillin."

Answered by AI

What is the difference between penicillin G benzathine and procaine?

"Benzathine is a salt form of penicillin G that is less soluble and provides a longer duration of action. Penicillin G procaine is given once daily and injected into the midlateral thigh or upper outer quadrant of the gluteus maximus."

Answered by AI

What is penicillin G procaine used for?

"Penicillin G Procaine is an antibiotic that is injected into a muscle to treat bacterial infections in different areas of the body. It is not effective in treating viral infections, such as the common cold."

Answered by AI

Is procaine penicillin the same as penicillin G?

"Procaine penicillin G is a combination of benzylpenicillin and the local anaesthetic agent procaine. It is slowly absorbed into the body after IM administration and hydrolysed to benzylpenicillin. This allows for a prolonged but low concentration of benzylpenicillin in the body."

Answered by AI

Clinical Trials for Penicillin G Procaine

Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Have you considered Penicillin G Procaine clinical trials? We made a collection of clinical trials featuring Penicillin G Procaine, we think they might fit your search criteria.Go to Trials
Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO
Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.
Phase 4
Recruiting
University of MissouriKevin M Klifto, DO, PharmD
Image of Hospital of the University of Pennsylvania in Philadelphia, United States.

11C-Trimethoprim Imaging for Bacterial Infection

18+
All Sexes
Philadelphia, PA
Patients with suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 30 subjects will participate in two different imaging cohorts. The Biodistribution cohort will include up to 5 patients referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution \[11C\]trimethoprim PET/CT scans over a period of approximately 2 ½ hours. The Dynamic cohort will include up to 25 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of \[11C\]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second \[11C\]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in \[11C\]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving. Patients will also undergo baseline lab tests complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and blood cultures. If these tests are done as part of clinical standard of care they will not need to be repeated for this study.
Phase 1
Waitlist Available
Hospital of the University of PennsylvaniaDavid Mankoff, MD PhD
Have you considered Penicillin G Procaine clinical trials? We made a collection of clinical trials featuring Penicillin G Procaine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security